The NEDD8 inhibitor MLN4924 (Pevonedistat), which selectively targets the NEDD8 E1-activating enzyme, has shown a strong anti-cancer response in pre-clinical studies and is now in Phase III clinical trials [11,21]. This evidence concerns the gene NEDD8 and cancer.